# Neowise

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neowise

- Industry: Biotechnology
- Headquarters: Suzhou, China
- Website: www.neowisebio.com
- Total disclosed funding: $57M
- Latest round: Series B (Oct 31, 2025)
- Investors on record: 12

## About

Founded in 2020 and based in Suzhou, China, Neowise Biotechnology, Co., Ltd., dba Neowise is an innovative biotechnology company focused on the discovery and development of TCR-T (T-cell receptor-engineered T cell) therapies for the treatment of solid tumors. The company aims to expand therapeutic targets and improve treatment options for cancer patients through advanced immunocell therapy technologies. In October 2025, Neowise raised over 200 million in Series B funding led by new investor Apricot Capital, with participation from new investors Delian Capital, Suzhou Angel Investment Guidance Fund and returning investors Oriza Holdings, Shenzhen Green Eco-Manufacture Hi-Tech Co., Ltd., Shanghai Tonggao Investment Management Co., LTD.
Neowise develops autologous TCR-T cell therapy drug candidates targeting tumor-associated antigens in solid tumors. Its core technology platform supports the discovery, validation, and development of antigen-specific TCRs, enabling multiple clinical-stage cell therapy pipelines.
The company’s revenue sources include out-licensing or partnering of proprietary TCR assets and future commercialization of clinical-stage and approved TCR-T therapies for solid tumors.

## Funding rounds

- Series B, Oct 31, 2025, $28M — Oriza Holdings, Shenzhen Green Eco-Manufacture Hi-Tech Co., Ltd, Delian Capital, Apricot Capital, Shanghai Tonggao Investment Management Co., LTD, Suzhou Angel Investment Guidance Fund
- Series A, Mar 15, 2023, $29M — Oriza Holdings, Shenzhen Green Eco-Manufacture Hi-Tech Co., Ltd, Marathon Venture Partners, TF Capital, Shanghai Tonggao Investment Management Co., LTD, Zhongxin Capital, Leader Venture Capital
- Series A, Oct 14, 2021 — Shanghai Jianyi Private Equity Fund Management, TF Capital
- Angel, Oct 30, 2020 — Baidu Ventures

## Investors

- Baidu Ventures (https://capitalatlas.ai/funds/baidu-ventures) — Angel
- Shanghai Jianyi Private Equity Fund Management (https://capitalatlas.ai/funds/shanghai-jianyi-private-equity-fund-management) — Series A
- TF Capital — Series A
- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Series A, Series B
- Shenzhen Green Eco-Manufacture Hi-Tech Co., Ltd — Series A, Series B
- Marathon Venture Partners (https://capitalatlas.ai/funds/marathon-venture-partners) — Series A
- Shanghai Tonggao Investment Management Co., LTD — Series A, Series B
- Zhongxin Capital — Series A
- Leader Venture Capital (https://capitalatlas.ai/funds/leader-venture-capital) — Series A
- Delian Capital (https://capitalatlas.ai/funds/delian-capital) — Series B
- Apricot Capital (https://capitalatlas.ai/funds/apricot-capital) — Series B
- Suzhou Angel Investment Guidance Fund (https://capitalatlas.ai/funds/suzhou-angel-investment-guidance-fund) — Series B